Controversies in the Management of the Anemia of Prematurity Using Single-Donor Red Blood Cell Transfusions and/or Recombinant Human Erythropoietin

2006 ◽  
Vol 20 (1) ◽  
pp. 34-44 ◽  
Author(s):  
Ronald G. Strauss
Keyword(s):  
Blood Cell ◽  
Red Blood Cell ◽  
Recombinant Human Erythropoietin ◽  
Human Erythropoietin ◽  
Single Donor ◽  
Anemia Of Prematurity ◽  
Red Blood Cell Transfusions

scholarly journals Iatrogenic Iron Overload in an End Stage Renal Disease Patient

2020 ◽  
Vol 13 (2) ◽  
pp. 760-763
Author(s):  
Majd M. Aldwairi ◽  
Mohamed A. Yassin
Keyword(s):  
Renal Failure ◽  
Blood Cell ◽  
Iron Overload ◽  
Red Blood Cell ◽  
Disease Patient ◽  
Intravenous Iron ◽  
Human Erythropoietin ◽  
Red Blood Cell Transfusions ◽  
Stage Renal Disease ◽  
End Stage

Iron overload is a common complication in patients with chronic renal failure treated with dialysis prior to the availability of recombinant human erythropoietin therapy. Iron overload was the result of hypoproliferative erythroid marrow function coupled with the need for frequent red blood cell transfusions to manage symptomatic anemia. The repetitive use of intravenous iron with or without the use of red blood cell transfusions also contributed to iron loading and was associated with iron deposition in liver parenchymal and reticuloendothelial cells. Here we report a 56-year-old female with end-stage renal failure who underwent kidney transplant twice and found to have iatrogenic iron overload with excess intravenous iron treated conservatively.

Changes in Red Blood Cell Volume under Recombinant Human Erythropoietin Therapy

2015 ◽  
pp. 52-58
Author(s):  
Reinhard Schmidt ◽  
Dietmar Lerche ◽  
Erhard D�rp ◽  
Roland Winkler ◽  
Horst Klinkmann
Keyword(s):  
Blood Cell ◽  
Cell Volume ◽  
Red Blood Cell ◽  
Recombinant Human Erythropoietin ◽  
Human Erythropoietin

Are single-donor red blood cell transfusions still relevant for preterm infants?

2020 ◽  
Vol 40 (7) ◽  
pp. 1075-1082
Author(s):  
Elodie Gouache ◽  
Jean-Yves Py ◽  
Béatrice Hérault ◽  
Elie Saliba ◽  
Geraldine Favrais
Keyword(s):  
Blood Cell ◽  
Preterm Infants ◽  
Red Blood Cell ◽  
Single Donor ◽  
Red Blood Cell Transfusions

scholarly journals Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs

Blood ◽  
1994 ◽  
Vol 83 (7) ◽  
pp. 1952-1957 ◽  
Author(s):  
AJ Mitus ◽  
JH Antin ◽  
CJ Rutherford ◽  
CJ McGarigle ◽  
MA Goldberg
Keyword(s):  
Bone Marrow ◽  
Blood Cell ◽  
Red Blood Cell ◽  
Recombinant Human Erythropoietin ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Red Blood Cell Transfusion ◽  
Allogeneic Bone ◽  
Human Erythropoietin ◽  
Transfusion Requirements

Abstract In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMT), we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-matched donors were enrolled. Donors treated with recombinant human erythropoietin (rHuEPO) were phlebotomized a median of 6 U (range, 4 to 11 U) of blood over a 5-week period. This donor-derived blood was available to the BMT donor or recipient as needed. Transplant recipients were also treated with rHuEPO post-BMT to hasten erythropoiesis. Five of 11 BMT recipients underwent transplant receiving only donor-derived red blood cell transfusion, compared with 0 of 11 concomitant control recipients (P = .04). In addition, the time to absolute reticulocyte count > or = 10(4)/microL was statistically shorter in the rHuEPO-treated recipient group. This study serves as a paradigm for hematopoietic growth factor use in allogeneic BMT to decrease or eliminate homologous transfusion exposures and to possibly hasten hematopoietic engraftment.

scholarly journals Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs

Blood ◽  
1994 ◽  
Vol 83 (7) ◽  
pp. 1952-1957 ◽  
Author(s):  
AJ Mitus ◽  
JH Antin ◽  
CJ Rutherford ◽  
CJ McGarigle ◽  
MA Goldberg
Keyword(s):  
Bone Marrow ◽  
Blood Cell ◽  
Red Blood Cell ◽  
Recombinant Human Erythropoietin ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Red Blood Cell Transfusion ◽  
Allogeneic Bone ◽  
Human Erythropoietin ◽  
Transfusion Requirements

In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMT), we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-matched donors were enrolled. Donors treated with recombinant human erythropoietin (rHuEPO) were phlebotomized a median of 6 U (range, 4 to 11 U) of blood over a 5-week period. This donor-derived blood was available to the BMT donor or recipient as needed. Transplant recipients were also treated with rHuEPO post-BMT to hasten erythropoiesis. Five of 11 BMT recipients underwent transplant receiving only donor-derived red blood cell transfusion, compared with 0 of 11 concomitant control recipients (P = .04). In addition, the time to absolute reticulocyte count > or = 10(4)/microL was statistically shorter in the rHuEPO-treated recipient group. This study serves as a paradigm for hematopoietic growth factor use in allogeneic BMT to decrease or eliminate homologous transfusion exposures and to possibly hasten hematopoietic engraftment.

Sign in / Sign up

Export Citation Format

Share Document